Confo Therapeutics is a clinical-stage biotechnology company dedicated to pioneering novel medicines targeting G-protein coupled receptors (GPCRs) for metabolic and endocrine diseases. Utilizing its proprietary Confo® technology platform, Confo Therapeutics develops both small molecules and antibody-based therapies, creating new treatment opportunities for patients. The company's pipeline includes programs such as CFTX-1554, a non-opioid treatment for neuropathic pain, and CFTX-2034, an SSTR5 agonist antibody for post-bariatric hypoglycemia. Confo Therapeutics is headquartered in Ghent, Belgium, and collaborates with leading pharmaceutical partners to advance its innovative therapies. (confotherapeutics.com )
Powered by DataScouts